BBP News and Press, Virtus LifeSci Biotech Products From 10/05/21

Taking a look at how the expected Q3 ’21 sector revenue growth rates have changed since mid-August ’21 or the unofficial end of Q2 ’21 earnings season. Per Bespoke’s research, the S&P 500 has now reached “extremely oversold” levels, worse ...

We’ve seen economic data in recent months moderate after record growth in the first half of 2021. In financials, the rise of many fintech companies and the growth of digital payments has really disrupted the traditional banking industry, creating new options for consumers. ...

Defensive stocks are often misunderstood. In recent years, even when they have delivered strong and steady earnings, returns have disappointed. After a period of underperformance for defensives, a broadening market can represent real opportunity. Beyond utilities, we believe that ...

In any market’s upswing, there are always going to be people who make the case that “it’s different this time”, and historically, most of the time, that argument doesn’t hold up. I have never seen so many interesting and novel therapeutic opportuniti...

From a consumer perspective, the consumer is actually now demanding a focus on environmental, social, governance factors. If public expectations for inflation do rise, that is going to be a change from years past. There’s going to be an opportunity to make medical progress ...

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...

Opportunities and risks in the healthcare sector. The next big areas of innovation in healthcare. Extreme winners and losers in the healthcare sector. For further details see: Building A Healthy Portfolio: Spotlight On Healthcare

In January 2020, only 0.24% of total medical claims in the U.S. were telemedicine-related. One year later, they totaled 7%. It took 15 years for e-commerce penetration to rise from less than 1% to over 7%. The pandemic helped telemedicine do it in one. Population-wide immunity to ...

This has been a long, long boom in the amount of money that's flowed into this sector, and I don't think I've ever seen anything like it in my own career. This has been VC money going into early-stage startups, it's been IPOs, it's been follow-on financing of already public companies....